These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15383641)

  • 21. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
    Rosencher N
    Anaesthesia; 2004 Aug; 59(8):803-10. PubMed ID: 15270973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
    Schulman S; Lundström T; Wålander K; Billing Clason S; Eriksson H
    Thromb Haemost; 2005 Oct; 94(4):820-4. PubMed ID: 16270637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA; Dorrell KA; Sandberg KR; Yerkey MW
    Rev Cardiovasc Med; 2004; 5(2):99-103. PubMed ID: 15184843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ; Lip GY
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
    Hellgren M; Johansson S; Eriksson UG; Wåhlander K
    BJOG; 2005 May; 112(5):579-83. PubMed ID: 15842280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ximelagatran: a new type of oral anticoagulant.
    Kwok L; Molckovsky D; Boucher M
    Int J Technol Assess Health Care; 2005; 21(4):480-6. PubMed ID: 16262971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B
    Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ximelagatran--a promising new drug in thromboembolic disorders.
    Petersen P
    Curr Pharm Des; 2005; 11(4):527-38. PubMed ID: 15725069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of ximelagatran.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):245-53. PubMed ID: 16123911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
    Teng R; Sarich TC; Eriksson UG; Hamer JE; Gillette S; Schützer KM; Carlson GF; Kowey PR
    J Clin Pharmacol; 2004 Sep; 44(9):1063-71. PubMed ID: 15317834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orally active direct thrombin inhibitors.
    Weitz J
    Semin Vasc Med; 2003 May; 3(2):131-8. PubMed ID: 15199476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ximelagatran for prevention and treatment of venous thromboembolism.
    Kwok L; Boucher M
    Issues Emerg Health Technol; 2004 Jun; (57):1-4. PubMed ID: 15214359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Ximelagatran for treatment of venous thromboembolism].
    Harenberg J; Fenyvesi T; Jörg I
    Hamostaseologie; 2002 Aug; 22(3):25-9. PubMed ID: 12215758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
    Harenberg J; Jörg I; Weiss C
    Int J Toxicol; 2006; 25(3):165-9. PubMed ID: 16717032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.
    Agnelli G; Eriksson BI; Cohen AT; Bergqvist D; Dahl OE; Lassen MR; Mouret P; Rosencher N; Andersson M; Bylock A; Jensen E; Boberg B;
    Thromb Res; 2009; 123(3):488-97. PubMed ID: 18485453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism.
    Agnelli G
    Drugs; 2004; 64 Suppl 1():47-52. PubMed ID: 15586627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral direct thrombin inhibitors in clinical development.
    Gustafsson D
    J Intern Med; 2003 Oct; 254(4):322-34. PubMed ID: 12974871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.